Drug Research
Novavax Awarded Funding from CEPI for COVID-19 Vaccine Development
Novavax, Inc., a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, announced that the Coalition for Epidemic Preparedness Innovations (CEPI) awarded an initial funding of $4 million to support Novavax’ efforts to develop a COVID-19 vaccine. CEPI...
News
Albireo Completes Enrollment in Phase 2 Study of Elobixibat in NASH/NAFLD
Albireo Pharma, Inc., a clinical-stage orphan pediatric liver disease company developing novel bile acid modulators, announced achievement of full patient enrollment in its Phase 2 clinical trial of elobixibat 5mg, a first-in-class, once-daily, orally available ileal bile acid transporter...
IT & Data Management
Beijing University of Chinese Medicine collaborates with Elsevier to launch first branch of traditional Chinese medicine taxonomy
Elsevier, a global leader in information analytics, specializing in science and health, launched the first branch of its Traditional Chinese Medicine (TCM) taxonomy in collaboration with Beijing University of Chinese Medicine (BUCM), a leader in the field of TCM...
Clinical Trials
Biocair to participate in cell and gene webinar to explore ongoing material sourcing challenges
Christopher Good, Director of Cell and Gene Therapy Logistics at Biocair, will explore ongoing material sourcing challenges for organisations moving from development to clinical and commercial manufacturing in an upcoming webinar taking place on 12 March 2020.
Critical considerations in...
News
Bactiguard Holding AB has completed the acquisition of Vigilenz Medical Devices and Vigilenz Medical Supplies
Bactiguard Holding AB has completed the acquisition of Vigilenz Medical Devices and Vigilenz Medical Supplies (together Vigilenz), which was announced on 4 February 2020.
All conditions precedent have been fulfilled and the first part of the total consideration, consisting of...
News
Gilead buys Forty Seven for $4.9 billion to bolster cancer drug pipeline
Gilead Sciences Inc (GILD.O) said it would buy Forty Seven Inc (FTSV.O) for $4.9 billion in cash, adding an experimental treatment that targets blood cancer to its portfolio of oncology drugs.
Shares of Forty Seven jumped 62%, trading slightly below...
IT & Data Management
Tandem Diabetes Care Announces FDA Designation of Basal-IQ Technology as an Interoperable Automated Glycemic Controller
Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, announced U.S. FDA clearance of its Basal-IQâ„¢ technology as an interoperable automated glycemic controller (iAGC). This is the second system to receive iAGC designation by the FDA,...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read